{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:04:40Z","timestamp":1790813080196,"version":"4.1.0"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Ischemic stroke remains a major cause of long-term disability worldwide. Despite advances in acute reperfusion therapies, many survivors experience persistent neurological deficits due to irreversible neuronal loss and limited endogenous repair, highlighting the need for effective regenerative strategies. Mesenchymal stem cells (MSCs) have emerged as promising candidates for cell-based therapy because of their multimodal paracrine effects, including immunomodulation, promotion of angiogenesis and neurogenesis, attenuation of neuroinflammation, and enhancement of endogenous neuroplasticity. This Concise Review synthesizes the current clinical evidence supporting MSC therapy for ischemic stroke, critically examines the biological and translational determinants of therapeutic efficacy, and discusses emerging strategies, including engineered MSCs, extracellular vesicle (EV)-based therapies, and integration with neurorehabilitation. A structured literature search of PubMed\/MEDLINE, Embase, Web of Science, and the Cochrane Library through June 2026 prioritized randomized controlled trials, systematic reviews, and meta-analyses. The largest contemporary meta-analysis, encompassing 30 clinical studies and 1217 participants, confirmed the favorable safety profile of MSC therapy while emphasizing the need for larger, standardized randomized trials to establish definitive clinical efficacy. Available evidence indicates that MSC therapy is generally safe, with serious treatment-related adverse events being uncommon, and may improve neurological impairment and functional recovery. However, heterogeneity in cell source, manufacturing protocols, administration route, treatment timing, dosing strategies, and patient selection continues to limit definitive conclusions regarding efficacy. Future progress will depend on standardized Good Manufacturing Practice-compliant manufacturing, validated potency assays, optimized patient selection, identification of the optimal therapeutic window, and integration of engineered MSCs, EV-based therapies, and combination approaches with neuromodulation.<\/jats:p>","DOI":"10.1093\/stmcls\/sxag052","type":"journal-article","created":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T18:25:39Z","timestamp":1789755939000},"source":"Crossref","is-referenced-by-count":0,"title":["Mesenchymal stem cell therapy for ischemic stroke: bridging clinical evidence and translational challenges"],"prefix":"10.1093","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-3117-1449","authenticated-orcid":false,"given":"Samson","family":"Selvaraj","sequence":"first","affiliation":[{"name":"Poovanthi Institute of Rehabilitation and Elder Care , Poovanthi, Madurai, Tamil Nadu 630611,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,9,21]]},"reference":[{"key":"2026093019470131000_sxag052-B1","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1016\/S1474-4422(24)00369-7","article-title":"Global, regional, and national burden of stroke and its risk factors, 1990-2021: a systematic analysis for the global burden of disease study 2021","volume":"23","author":"GBD 2021 Stroke Risk Factor Collaborators","year":"2024","journal-title":"Lancet Neurol"},{"key":"2026093019470131000_sxag052-B2","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1212\/CON.0000000000000420","article-title":"Treatment of acute ischemic stroke","volume":"23","author":"Rabinstein","year":"2017","journal-title":"Continuum (Minneap Minn)"},{"key":"2026093019470131000_sxag052-B3","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/S1474-4422(18)30500-3","article-title":"Stroke in China: advances and challenges in epidemiology, prevention, and management","volume":"18","author":"Wu","year":"2019","journal-title":"Lancet Neurol"},{"key":"2026093019470131000_sxag052-B4","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1038\/nrneurol.2010.200","article-title":"Neuroplasticity in the context of motor rehabilitation after stroke","volume":"7","author":"Dimyan","year":"2011","journal-title":"Nat Rev Neurol"},{"key":"2026093019470131000_sxag052-B5","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1177\/0963689718795424","article-title":"Transplanting mesenchymal stem cells for treatment of ischemic stroke","volume":"27","author":"Wang","year":"2018","journal-title":"Cell Transplant"},{"key":"2026093019470131000_sxag052-B6","doi-asserted-by":"publisher","first-page":"9923566","DOI":"10.1155\/2021\/9923566","article-title":"Progress in mesenchymal stem cell therapy for ischemic stroke","volume":"2021","author":"Guo","year":"2021","journal-title":"Stem Cells Int"},{"key":"2026093019470131000_sxag052-B7","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1186\/s13287-019-1447-y","article-title":"MSC-secreted TGF-\u03b2 regulates lipopolysaccharide-stimulated macrophage M2-like polarization via the Akt\/FoxO1 pathway","volume":"10","author":"Liu","year":"2019","journal-title":"Stem Cell Res Ther"},{"key":"2026093019470131000_sxag052-B8","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1002\/stem.430","article-title":"A long-term follow-up study of intravenous autologous mesenchymal stem cell transplantation in patients with ischemic stroke","volume":"28","author":"Lee","year":"2010","journal-title":"Stem Cells (1981)"},{"key":"2026093019470131000_sxag052-B9","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1093\/stcltm\/szae040","article-title":"Efficacy and safety of mesenchymal stem cell therapies for ischemic stroke: a systematic review and meta-analysis","volume":"13","author":"Shen","year":"2024","journal-title":"Stem Cells Transl Med"},{"key":"2026093019470131000_sxag052-B10","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.3390\/biom11091316","article-title":"Combination of stem cells and rehabilitation therapies for ischemic stroke","volume":"11","author":"Berlet","year":"2021","journal-title":"Biomolecules"},{"key":"2026093019470131000_sxag052-B11","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1002\/cne.22038","article-title":"Stem cells for ischemic brain injury: a critical review","volume":"515","author":"Burns","year":"2009","journal-title":"J Comp Neurol"},{"key":"2026093019470131000_sxag052-B12","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/s41392-022-00932-0","article-title":"The secretion profile of mesenchymal stem cells and potential applications in treating human diseases","volume":"7","author":"Han","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"2026093019470131000_sxag052-B13","doi-asserted-by":"publisher","first-page":"6894","DOI":"10.3390\/ijms21186894","article-title":"Pleiotropic effects of exosomes as a therapy for stroke recovery","volume":"21","author":"Ueno","year":"2020","journal-title":"Int J Mol Sci"},{"key":"2026093019470131000_sxag052-B14","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1002\/ana.20501","article-title":"Autologous mesenchymal stem cell transplantation in stroke patients","volume":"57","author":"Bang","year":"2005","journal-title":"Ann Neurol"},{"key":"2026093019470131000_sxag052-B15","doi-asserted-by":"publisher","first-page":"2835","DOI":"10.1161\/STROKEAHA.119.026318","article-title":"Phase I\/II study of safety and preliminary efficacy of intravenous allogeneic mesenchymal stem cells in chronic stroke","volume":"50","author":"Levy","year":"2019","journal-title":"Stroke"},{"key":"2026093019470131000_sxag052-B16","doi-asserted-by":"publisher","first-page":"9636897221083863","DOI":"10.1177\/09636897221083863","article-title":"Final results of allogeneic adipose tissue\u2013derived mesenchymal stem cells in acute ischemic stroke (AMASCIS): a phase II, randomized, double-blind, placebo-controlled, single-center, pilot clinical trial","volume":"31","author":"de Celis-Ruiz","year":"2022","journal-title":"Cell Transplant"},{"key":"2026093019470131000_sxag052-B17","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/S1474-4422(17)30046-7","article-title":"Safety and efficacy of multipotent adult progenitor cells in acute ischaemic stroke (MASTERS): a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"16","author":"Hess","year":"2017","journal-title":"Lancet Neurol"},{"key":"2026093019470131000_sxag052-B18","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1007\/s12975-020-00787-z","article-title":"Autologous mesenchymal stem cells improve motor recovery in subacute ischemic stroke: a randomized clinical trial","volume":"11","author":"Jaillard","year":"2020","journal-title":"Transl Stroke Res"},{"key":"2026093019470131000_sxag052-B19","doi-asserted-by":"publisher","first-page":"e1012","DOI":"10.1212\/WNL.0000000000011440","article-title":"Efficacy and safety of intravenous mesenchymal stem cells for ischemic stroke","volume":"96","author":"Chung","year":"2021","journal-title":"Neurology"},{"key":"2026093019470131000_sxag052-B20","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/j.stem.2018.05.004","article-title":"Mesenchymal stromal cells: clinical challenges and therapeutic opportunities","volume":"22","author":"Galipeau","year":"2018","journal-title":"Cell Stem Cell"},{"key":"2026093019470131000_sxag052-B21","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.jcyt.2015.11.008","article-title":"International Society for Cellular Therapy perspective on immune functional assays for mesenchymal stromal cells as potency release criterion for advanced phase clinical trials","volume":"18","author":"Galipeau","year":"2016","journal-title":"Cytotherapy"},{"key":"2026093019470131000_sxag052-B22","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.stem.2014.01.013","article-title":"MSC-based product characterization for clinical trials: an FDA perspective","volume":"14","author":"Mendicino","year":"2014","journal-title":"Cell Stem Cell"},{"key":"2026093019470131000_sxag052-B23","doi-asserted-by":"publisher","first-page":"17986","DOI":"10.3390\/ijms140917986","article-title":"Comparative analysis of human mesenchymal stem cells from bone marrow, adipose tissue, and umbilical cord blood as sources of cell therapy","volume":"14","author":"Jin","year":"2013","journal-title":"Int J Mol Sci"},{"key":"2026093019470131000_sxag052-B24","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1177\/0271678X17731964","article-title":"Age of donor of human mesenchymal stem cells affects structural and functional recovery after cell therapy following ischaemic stroke","volume":"38","author":"Yamaguchi","year":"2018","journal-title":"J Cereb Blood Flow Metab"},{"key":"2026093019470131000_sxag052-B25","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1161\/ATVBAHA.122.318559","article-title":"Hypoxia-preconditioned bone marrow mesenchymal stem cells improved cerebral collateral circulation and stroke outcome in mice","volume":"43","author":"Tian","year":"2023","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2026093019470131000_sxag052-B26","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s13287-017-0558-6","article-title":"The therapeutic potential of three-dimensional multipotent mesenchymal stromal cell spheroids","volume":"8","author":"Petrenko","year":"2017","journal-title":"Stem Cell Res Ther"},{"key":"2026093019470131000_sxag052-B27","doi-asserted-by":"publisher","first-page":"7795","DOI":"10.3390\/ijms21207795","article-title":"Enhancing the therapeutic potential of CCL2-overexpressing mesenchymal stem cells in acute stroke","volume":"21","author":"Lee","year":"2020","journal-title":"Int J Mol Sci"},{"key":"2026093019470131000_sxag052-B28","doi-asserted-by":"publisher","first-page":"113542","DOI":"10.1016\/j.expneurol.2020.113542","article-title":"Combinatorial intranasal delivery of bone marrow mesenchymal stem cells and insulin-like growth factor-1 improves neurovascularization and functional outcomes following focal cerebral ischemia in mice","volume":"337","author":"Shen","year":"2021","journal-title":"Exp Neurol"},{"key":"2026093019470131000_sxag052-B29","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.3390\/biomedicines11041231","article-title":"Bioengineered mesenchymal-stromal-cell-derived extracellular vesicles as an improved drug delivery system: methods and applications","volume":"11","author":"Ulpiano","year":"2023","journal-title":"Biomedicines"},{"key":"2026093019470131000_sxag052-B30","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.bioactmat.2025.01.014","article-title":"A review: carrier-based hydrogels containing bioactive molecules and stem cells for ischemic stroke therapy","volume":"49","author":"Yin","year":"2025","journal-title":"Bioact Mater"},{"key":"2026093019470131000_sxag052-B31","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1177\/1747493017714176","article-title":"Biomarkers of stroke recovery: consensus-based core recommendations from the stroke recovery and rehabilitation roundtable","volume":"12","author":"Boyd","year":"2017","journal-title":"Int J Stroke"}],"container-title":["Stem Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/stmcls\/advance-article-pdf\/doi\/10.1093\/stmcls\/sxag052\/71299145\/sxag052.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/stmcls\/article-pdf\/44\/10\/sxag052\/71299145\/sxag052.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/stmcls\/article-pdf\/44\/10\/sxag052\/71299145\/sxag052.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T23:47:08Z","timestamp":1790812028000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/stmcls\/article\/doi\/10.1093\/stmcls\/sxag052\/8826346"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,21]]},"references-count":31,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,9,22]]}},"URL":"https:\/\/doi.org\/10.1093\/stmcls\/sxag052","relation":{},"ISSN":["1066-5099","1549-4918"],"issn-type":[{"value":"1066-5099","type":"print"},{"value":"1549-4918","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10]]},"published":{"date-parts":[[2026,9,21]]},"article-number":"sxag052"}}